These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 32423769)

  • 21. ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis.
    Quartier P; Baptiste A; Despert V; Allain-Launay E; Koné-Paut I; Belot A; Kodjikian L; Monnet D; Weber M; Elie C; Bodaghi B;
    Ann Rheum Dis; 2018 Jul; 77(7):1003-1011. PubMed ID: 29275333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial.
    Suhler EB; Lowder CY; Goldstein DA; Giles T; Lauer AK; Kurz PA; Pasadhika S; Lee ST; de Saint Sardos A; Butler NJ; Tessler HH; Smith JR; Rosenbaum JT
    Br J Ophthalmol; 2013 Apr; 97(4):481-6. PubMed ID: 23376607
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term assessment of clinical response to adalimumab therapy in refractory ulcerative colitis.
    Hussey M; Mc Garrigle R; Kennedy U; Holleran G; Kevans D; Ryan B; Breslin N; Mahmud N; McNamara D
    Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):217-21. PubMed ID: 26587866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
    Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD
    J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients.
    Riancho-Zarrabeitia L; Calvo-Río V; Blanco R; Mesquida M; Adan AM; Herreras JM; Aparicio Á; Peiteado-Lopez D; Cordero-Coma M; García Serrano JL; Ortego-Centeno N; Maíz O; Blanco A; Sánchez-Bursón J; González-Suárez S; Fonollosa A; Santos-Gómez M; González-Vela C; Loricera J; Pina T; González-Gay MA
    Semin Arthritis Rheum; 2015 Dec; 45(3):361-8. PubMed ID: 26092330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adalimumab therapy for refractory uveitis: a pilot study.
    Diaz-Llopis M; García-Delpech S; Salom D; Udaondo P; Hernández-Garfella M; Bosch-Morell F; Quijada A; Romero FJ
    J Ocul Pharmacol Ther; 2008 Jun; 24(3):351-61. PubMed ID: 18476805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sporadic Blau syndrome treated with adalimumab.
    Millington GWM; Dobson J; Holden S; Waters G; Puvanachandra N; Close R; Bale P; Armon K
    Clin Exp Dermatol; 2019 Oct; 44(7):811-813. PubMed ID: 31232485
    [No Abstract]   [Full Text] [Related]  

  • 28. Retrospective analysis of children with uveitis treated with infliximab.
    Tugal-Tutkun I; Ayranci O; Kasapcopur O; Kir N
    J AAPOS; 2008 Dec; 12(6):611-3. PubMed ID: 18930672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum cytokine profile in adalimumab-treated refractory uveitis patients: decreased IL-22 correlates with clinical responses.
    Cordero-Coma M; Calleja S; Llorente M; Rodriguez E; Franco M; Ruiz de Morales JG
    Ocul Immunol Inflamm; 2013 Jun; 21(3):212-9. PubMed ID: 23617852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
    Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
    Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Long-term adalimumab therapy in ulcerative colitis in clinical practice: result of the Hungarian multicenter prospective study].
    Rutka M; Bálint A; Farkas K; Palatka K; Lakner L; Miheller P; Rácz I; Hegede G; Vincze Á; Horváth G; Szabó A; Nagy F; Szepes Z; Gábor Z; Zsigmond F; Zsóri Á; Juhász M; Csontos Á; Szűcs M; Bor R; Milassin Á; Molnár T
    Orv Hetil; 2016 May; 157(18):706-11. PubMed ID: 27106726
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of Adalimumab in Ulcerative Colitis Refractory to Conventional Therapy in Routine Clinical Practice.
    Bálint A; Farkas K; Palatka K; Lakner L; Miheller P; Rácz I; Hegede G; Vincze Á; Horváth G; Szabó A; Nagy F; Szepes Z; Gábor Z; Zsigmond F; Zsóri Á; Juhász M; Csontos Á; Szűcs M; Bor R; Milassin Á; Rutka M; Molnár T
    J Crohns Colitis; 2016 Jan; 10(1):26-30. PubMed ID: 26392413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical experience with adalimumab in the treatment of ocular Behçet disease.
    Bawazeer A; Raffa LH; Nizamuddin SH
    Ocul Immunol Inflamm; 2010 Jun; 18(3):226-32. PubMed ID: 20482404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravitreal adalimumab for refractory uveitis-related macular edema.
    Androudi S; Tsironi E; Kalogeropoulos C; Theodoridou A; Brazitikos P
    Ophthalmology; 2010 Aug; 117(8):1612-6. PubMed ID: 20378179
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adalimumab therapy for refractory uveitis: a pilot study.
    Callejas-Rubio JL; Sánchez-Cano D; Serrano JL; Ortego-Centeno N
    J Ocul Pharmacol Ther; 2008 Dec; 24(6):613-4; author reply 614. PubMed ID: 19049264
    [No Abstract]   [Full Text] [Related]  

  • 36. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial.
    Nguyen QD; Merrill PT; Jaffe GJ; Dick AD; Kurup SK; Sheppard J; Schlaen A; Pavesio C; Cimino L; Van Calster J; Camez AA; Kwatra NV; Song AP; Kron M; Tari S; Brézin AP
    Lancet; 2016 Sep; 388(10050):1183-92. PubMed ID: 27542302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor Necrosis Factor Inhibitors Provide Longterm Clinical Benefits in Pediatric and Young Adult Patients with Blau Syndrome.
    Nagakura T; Wakiguchi H; Kubota T; Yamatou T; Yamasaki Y; Nonaka Y; Nerome Y; Akaike H; Takezaki T; Imanaka H; Kawano Y; Takei S
    J Rheumatol; 2017 Apr; 44(4):536-538. PubMed ID: 28604349
    [No Abstract]   [Full Text] [Related]  

  • 38. Biologic response modifier therapy for psoriatic ocular inflammatory disease.
    Huynh N; Cervantes-Castaneda RA; Bhat P; Gallagher MJ; Foster CS
    Ocul Immunol Inflamm; 2008; 16(3):89-93. PubMed ID: 18569794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized Controlled Study to Evaluate the Efficacy of Adalimumab in Patients with Different Forms of Refractory Uveitis.
    Mackensen F; Heinz C; Jakob E; Grewing V; Lorenz HM; Heiligenhaus A; Max R; Becker MD
    Ocul Immunol Inflamm; 2018; 26(7):1015-1022. PubMed ID: 29286865
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials.
    Sheppard J; Joshi A; Betts KA; Hudgens S; Tari S; Chen N; Skup M; Dick AD
    JAMA Ophthalmol; 2017 Jun; 135(6):511-518. PubMed ID: 28426849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.